Another view of the history of antipsychotic drug discovery and development

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Molecular Psychiatry

• Publication date

  2012-12-01

• Fields of study

  Medicine, Psychology, History

• Identifiers
  DOI 10.1038/mp.2012.121PMID 22889923
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.

  2012cited by this paper
• Genome-wide association studies of schizophrenia: does bigger lead to better results?

  2012cited by this paper
• Methodological issues in negative symptom trials.

  2011cited by this paper
• The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

  2010cited by this paper
• Toward new approaches to psychotic disorders: the NIMH Research Domain Criteria project.

  2010cited by this paper
• The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.

  2010cited by this paper
• Research domain criteria (RDoC): toward a new classification framework for research on mental disorders.

  2010cited by this paper
• The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.

  2010cited by this paper
• EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

  2009cited by this paper
• A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.

  2009cited by this paper
• The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities

  2008cited by this paper
• Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.

  2008cited by this paper
• Deconstructing Psychosis conference February 2006: the validity of schizophrenia and alternative approaches to the classification of psychosis.

  2007cited by this paper
• Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy.

  2007cited by this paper
• Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

  2006cited by this paper
• The NIMH-MATRICS consensus statement on negative symptoms.

  2006cited by this paper
• Dopamine, prediction error and associative learning: A model-based account

  2006cited by this paper
• History of the discovery and clinical introduction of chlorpromazine.

  2005cited by this paper
• A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

  2005cited by this paper
• The shift of psychiatric inpatient care from hospitals to jails and prisons.

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005cited by this paper
• Program to improve cognitive functioning in patients with schizophrenia: reflections.

  2004cited by this paper
• Clinical constructs and therapeutic discovery.

  2004cited by this paper
• The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia.

  2003cited by this paper
• Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

  2003cited by this paper
• Dementia praecox and paraphrenia

  2002cited by this paper
• The Creation of Psychopharmacology

  2002cited by this paper
• How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment.

  2001cited by this paper
• Primary and secondary hypohedonia.

  2001cited by this paper
• Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.

  2000cited by this paper
• Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.

  1999cited by this paper
• A historical perspective of clozapine.

  1999cited by this paper
• Mental ills and bodily cures : psychiatric treatment in the first half of the twenthieth century

  1999cited by this paper
• The risk of medication-free research.

  1997cited by this paper
• Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.

  1997cited by this paper
• Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients.

  1997cited by this paper
• The rationale and ethics of medication-free research in schizophrenia.

  1997cited by this paper
• Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.

  1996cited by this paper
• Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

  1994cited by this paper
• Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

  1988cited by this paper
• Social adjustment and cognitive performance of high-risk children.

  1985cited by this paper
• The use of depot neuroleptics: clinical experience in the United States.

  1984cited by this paper
• The use of depot neuroleptics: clinical experience in the United States.

  1984cited by this paper
• Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

  1976cited by this paper
• Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs

  1976cited by this paper
• Overview: maintenance therapy in psychiatry: I. Schizophrenia.

  1975cited by this paper
• Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons.

  1975cited by this paper
• The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs.

  1974cited by this paper
• Diagnosis and Drug Treatment of Psychiatric Disorders

  1969cited by this paper
• Treatment of schizophrenia : a comparative study of five treatment methods

  1968cited by this paper
• [Dementia praecox or the group of schizophrenias].

  1968cited by this paper
• RESERPINE IN SCHIZOPHRENIA

  1958cited by this paper
• Intensive cortisone therapy in schizophrenia.

  1956cited by this paper
• Cortisone in the treatment of schizophrenia.

  1952cited by this paper
• Lithium salts in the treatment of psychotic excitement.

  1949cited by this paper

• Inflammation in Schizophrenia: The Role of Disordered Oscillatory Mechanisms

  2025cites this paper
• The 3q Oncogene SEC62 Predicts Response to Neoadjuvant Chemotherapy and Regulates Tumor Cell Migration in Triple Negative Breast Cancer

  2023cites this paper
• The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders.

  2023cites this paper
• Factors associated with daily use of benzodiazepines/tranquilizers and opioids among people who use drugs.

  2023cites this paper
• Adding pre-emptive anticholinergics to antipsychotics: Is it justified?

  2022cites this paper
• The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets

  2022cites this paper
• Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-naïve schizophrenia.

  2022cites this paper
• The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets

  2022cites this paper
• Seventy Years of Treating Delusional Disorder with Antipsychotics: A Historical Perspective

  2022cites this paper
• Effects of Blockade of Cholinesterase on Negative Disorders in Schizophrenia

  2022cites this paper
• Schizophrenia: Antipsychotics and drug development

  2021cites this paper
• Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies

  2021cites this paper
• [An effect of cholinesterase blockade on negative symptoms in schizophrenia].

  2021cites this paper
• A schizophrenia risk factor induces marked anatomical deficits at GABAergic‐dopaminergic synapses in the rat ventral tegmental area: Essential evidence for new targeted therapies

  2021cites this paper
• History of Antipsychotics

  2021cites this paper
• Involvement of anti-inflammatory, antioxidant, and BDNF up-regulating properties in the antipsychotic-like effect of the essential oil of Alpinia zerumbet in mice: a comparative study with olanzapine

  2021cites this paper
• Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder.

  2021cites this paper
• Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease.

  2020cites this paper
• Lurasidone – pharmacodynamic and pharmacokinetic properties, clinical potential and interaction risk

  2020cites this paper
• Safety and efficacy of pharmacologic agents used for rapid tranquilization of emergency department patients with acute agitation or excited delirium

  2020cites this paper
• Challenges in the Relationships between Psychological and Biological Phenomena in Psychopathology

  2020cites this paper
• ‘Not Left in Limbo’: Service User Experiences of Mental Health Nurse Prescribing in Home Care Settings

  2020cites this paper
• The Vital Role of a Full Continuum of Psychiatric Care Beyond Beds.

  2020cites this paper
• Effects of Doxycycline in Swiss Mice Predictive Models of Schizophrenia

  2020cites this paper
• Antidepressants and antipsychotic agents as repurposable oncological drug candidates.

  2020cites this paper
• Psychopharmacology: A Brief Overview of Its History

  2020cites this paper
• Modulation of extrasynaptic GABAA alpha 5 receptors in the ventral hippocampus normalizes physiological and behavioral deficits in a circuit specific manner

  2019cites this paper
• The story of antipsychotics: A metaphorical overview

  2019influential citation
• Investigation of betaine as a novel psychotherapeutic for schizophrenia

  2019cites this paper
• How Neuroscience Is Informing Treatments: Ethical Issues.

  2019cites this paper
• The Life Course Paradigm as a Lens for Holistic Nursing Research in Older Adults Diagnosed With Schizophrenia

  2019cites this paper
• Antipsychotic drugs v. barbiturates or benzodiazepines used as active placebos for schizophrenia: a systematic review and meta-analysis

  2019cites this paper
• Documentation of antipsychotic-related adverse drug reactions: An educational intervention

  2019cites this paper
• A HISTÓRIA DO PRIMEIRO SERVIÇO PSIQUIÁTRICO EM HOSPITAL GERAL DO BRASIL

  2019cites this paper
• History and Future of Antipsychotic Drugs

  2019cites this paper
• Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia.

  2018cites this paper
• The Relationship Between the Hearing Distressing Voices Simulation and Changes in Empathy Among Master’s Students in Counseling

  2018cites this paper
• Translational Significance of Selective Estrogen Receptor Modulators in Psychiatric Disorders

  2018cites this paper
• Prevention and Treatment of Obesity and Metabolic Dysfunction in Children with Major Behavioral Disorders: Second-Generation Antipsychotics

  2018cites this paper
• General Psychology (Fall 2018)

  2018cites this paper
• A systems neuroscience perspective on treatment resistant schizophrenia : the role of cognitive control, reinforcement learning, and myelination

  2018cites this paper
• Leveraging genome characteristics to improve gene discovery for putamen subcortical brain structure

  2017cites this paper
• Schizophrenia Spectrum Disorders

  2017cites this paper
• Let’s talk about Secs: Sec61, Sec62 and Sec63 in signal transduction, oncology and personalized medicine

  2017cites this paper
• Away for the Homeland: Why Students Fought to Keep Intermountain Indian School Open

  2016cites this paper
• Identification of SEC62 as a potential marker for 3q amplification and cellular migration in dysplastic cervical lesions

  2016cites this paper
• A novel pipeline for drug discovery in neuropsychiatric disorders using high-content single-cell screening of signalling network responses ex vivo

  2016influential citation
• Synthesis and pharmacological characterization of novel N-(trans-4-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)cyclohexyl)amides as potential multireceptor atypical antipsychotics.

  2016cites this paper
• Connectomics in Schizophrenia: From Early Pioneers to Recent Brain Network Findings.

  2016cites this paper
• Valutazione dell'appropriatezza prescrittiva in psichiatria: un progetto di clinical audit nella ASL di Caserta Evaluation of therapeutical appropriateness in psychiatric treatment of schizophrenia, by integrating computer data records with clinical audit results

  2016cites this paper
• AMIGO-Kv 2 . 1 Potassium Channel Complex : Identification and Association with Schizophrenia-Related Phenotypes

  2015cites this paper
• The Psychosis Response Guide: How to Help Young People in Psychiatric Crises

  2015cites this paper
• Investigating the functional significance of genome-wide variants associated with antipsychotic treatment response in schizophrenia

  2015cites this paper
• The relationship between second-generation antipsychotic medication adherence and negative symptoms in first-episode schizophrenia

  2015cites this paper
• [Evaluation of therapeutical appropriateness in psychiatric treatment of schizophrenia, by integrating computer data records with clinical audit results].

  2015cites this paper
• Novel Atypical Antipsychotics: Metabolism and Therapeutic Drug Monitoring (TDM).

  2015cites this paper
• General Psychology: An Introduction

  2015cites this paper
• Stratified medicine for mental disorders.

  2014cites this paper
• Mental health crisis intervention : a discourse analysis involving service users, families, nurses and the police : a thesis presented in fulfilment of requirements for the degree of Doctor of Philosophy in Nursing at Massey University, Palmerston North, New Zealand

  2014cites this paper
• Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in Greece

  2014cites this paper
• The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia.

  2014cites this paper
• Patterns of Antipsychotic Prescription to Patients with Schizophrenia in Korea: Results from the Health Insurance Review & Assessment Service-National Patient Sample

  2014cites this paper
• Targeting cell migration and the endoplasmic reticulum stress response with calmodulin antagonists: a clinically tested small molecule phenocopy of SEC62 gene silencing in human tumor cells

  2013cites this paper
• Utility of Combined Treatment with Antipsychotic and Antidepressant Drugs: Scientific Rationales and Clinical Implications

  2013cites this paper
• Perspectives on reasons for non-adherence to medication in persons with schizophrenia in Ethiopia: a qualitative study of patients, caregivers and health workers

  2013cites this paper
• Pharmacological approaches to treating negative symptoms: a review of clinical trials.

  2013cites this paper
• A case of paranoid schizophrenia and severe antipsychotic-induced Parkinson's disorder treated with a combination of olanzapine and lurasidone.

  2013cites this paper